BePharma, a global networking event dedicated to the pharmaceutical industry, will take place on March 16–18, 2026 in Mexico City, Mexico. Distinct from traditional trade fairs and exhibition-based formats, the event eliminates standard booth setups and instead centres on structured negotiation tables designed to facilitate direct corporate partnerships. By prioritising pre-arranged B2B meetings over product displays, BePharma aims to accelerate distribution agreements, licensing discussions, and cross-border collaborations within the global pharma supply chain.
Structured B2B Negotiation Model Driving Operational Efficiency
BePharma has been designed as a results-oriented B2B platform that prioritises time efficiency for company representatives. Through a dedicated digital scheduling system, participants arrange 30-minute pre-qualified meetings before the event, enabling them to focus exclusively on business negotiations throughout the three-day programme. This structured model is intended to accelerate key commercial processes, including licensing agreements, distribution partnerships, and strategic asset collaborations. By concentrating on targeted discussions rather than exhibition exposure, the platform enhances deal-making efficiency within the pharmaceutical value chain.
Broad Portfolio of Products and Services
Collaboration opportunities at BePharma are organised across the following strategic segments:
- Prescription (Rx) and Over-the-Counter (OTC) Medicines,
- Dietary Supplements and Nutraceuticals,
- Dermocosmetic and Dermatological Health Products,
- Medical Devices and Related Industrial Services.
BePharma 2026 by the Numbers
Since its launch in 2012, BePharma has completed 18 editions, bringing together more than 1,100 companies from 75 countries worldwide. According to the latest figures for the 2026 edition, 139 companies from 35 different countries have already confirmed their participation. Having facilitated over 18,000 B2B meetings in previous years, the platform continues to demonstrate its commercial consistency and sustained relevance within the pharmaceutical sector.
Mexico City’s strong infrastructure and logistical connectivity further enhance the event’s positioning, enabling BePharma to serve as a strategic gateway for international pharmaceutical companies seeking to expand their footprint in Latin America and other global markets. Within a secure and well-structured environment, participants will have the opportunity to explore new market prospects, strengthen distribution networks, and develop their product portfolios through targeted business negotiations.
FUAR HABER ONLINE